All News

ra.hands2_.JPG

Best of 2025: Hydroxychloroquine for Everyone

d Jack Cush, MD

Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based on its merit.

Read Article
GCA.glossary.wordle

Best of 2025: Glossary for Giant Cell Arteritis

d Jack Cush, MD

Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.

Read Article
steroids.prednisone.pills_.jpg

Best of 2025: Glucocorticoids in SLE: how to start, how to follow, how to stop

d Guillermo Ruiz-Irastorza, MD, PhD

Current guidelines recommend limiting the use of glucocorticoids by coining the new concept of “bridging therapy”, that is, use GCs when the disease is active and get rid of them as soon as you can. This way of thinking is conceptually attractive, however, the formula for translation to real life settings is not included.

Read Article
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Tm8m43ZXBM https://t.co/GWLPR5y3d2

Links:

Dr. John Cush RheumNow ( View Tweet)
2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. https://t.co/2NFwTllLZa https://t.co/S7Cwzbgnde

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 https://t.co/yzQVt1fLKW https://t.co/hrbEeppZhW

Links:

Dr. John Cush RheumNow ( View Tweet)
APP Pearls “Point out to every patient with gout that poorly controlled gout will increase their risk of CV events and mortality” - Emma Bavage, NP

Dr. John Cush RheumNow ( View Tweet)

“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

Dr. John Cush RheumNow ( View Tweet)

Best of 2025: Methotrexate intolerance in rheumatoid arthritis Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week. https://t.co/hzfF7UVKVI
Dr. John Cush RheumNow ( View Tweet)
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/KacbtcMn5G
Dr. John Cush RheumNow ( View Tweet)
Algorithm for the treatment of calcinosis #calcinosis #ACR24 https://t.co/NZhP7Enzrp https://t.co/I0HLtYjzgb

Links:

Dr. John Cush RheumNow ( View Tweet)
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/PTJPhcvnzC
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Overview of the VEXAS Syndrome A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome. https://t.co/O3BoOElcbT https://t.co/0hSEWqMFVf

Links:

Dr. John Cush RheumNow ( View Tweet)
Inflammatory vs. Noninflammatory Pain https://t.co/ZZLMnT8IVO https://t.co/dnZHqV1jcK

Links:

Dr. John Cush RheumNow ( View Tweet)
Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: https://t.co/Fn76PiGsPl Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/JpyE3T7Atj

Links:

Dr. John Cush RheumNow ( View Tweet)
APP Pearls “Do not order a test if you do not know how to interpret the results whether normal or abnormal” - Madison Chastain, CRNP

Dr. John Cush RheumNow ( View Tweet)

Is the term polymyositis obsolete?.. now being replaced by dermatomyositis, necrotizing myopathy, inclusion body myositis, antisynthetase syndrome & overlap myositis. Full read overview of inflammatory myositis & new treatments from Joint Bone & Spine https://t.co/X46sptp1Ax https://t.co/M80026Z3Ur

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/ICSDysexOR
Dr. John Cush RheumNow ( View Tweet)
Review of IL-1 family cytokines in inflammation and immunity - including, IL-1, IL-18, IL-33, IL-36, IL-37, IL-38, IL-1Ra, etc. Full read -- Good Reference!! https://t.co/01o05qYPjU https://t.co/M02xrvxKre

Links:

Dr. John Cush RheumNow ( View Tweet)
APP Pearls “Never stop learning—rheumatology is full of surprises” - Kayla Carlucci, FNP-BC

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×